Event time: 事件时间：
Published: 文章发布：
Key Results
Actual vs Consensus
EPS: $1.83 vs -$0.86 estimate, beat.Revenue: $431M vs $404M estimate, beat+6.7%.Profitability and Cash Flow
Period: 2026 Q3 period ended 2026-09-30Revenue: $431M; YoY: +50.1%; QoQ: +18.4%Gross profit: $393M; Gross margin: 91.2%Operating income: $56M; Operating margin: 13.0%; YoY: +149.1%; QoQ: +199.4%Net income: $55M; GAAP diluted EPS: $1.83; YoY: +148.6%; QoQ: +195.7%Operating cash flow: $121M; Capex: $4M; Free cash flow: $117MOfficial release: Madrigal Pharmaceuticals Reports Third-Quarter 2026 Financial Results and Provides Corporate Updates
核心结果
实际值与市场预期
EPS：$1.83 vs -$0.86 预期，高于预期。营收：$431M vs $404M 预期，高于预期+6.7%。财务指标
期间：2026 Q3（截至 2026-09-30）营收：$431M；同比：+50.1%；环比：+18.4%毛利润：$393M；毛利率：91.2%经营利润：$56M；经营利润率：13.0%；同比：+149.1%；环比：+199.4%净利润：$55M；GAAP 稀释 EPS：$1.83；同比：+148.6%；环比：+195.7%经营现金流：$121M；资本开支：$4M；自由现金流：$117M
